The VEGF/VEGFR signaling axis remains central to antiangiogenic therapy in HCC, supported by decades of clinical success and emerging synergies with immunotherapy (83, 84) (Table 1). This evidence concerns the gene VEGFA and hepatocellular carcinoma.